Sulfonylpyrroles

Details Sulfonylpyrroles Sulfonylpyrroles

2005-03-10

2010-11-30

Havlin, Robert (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S424000

Reexamination Certificate

active

07842820

ABSTRACT:
Compounds of the formula Iin which the substitutents have the definitions provided in the specification, are novel, effective HDAC inhibitors.

REFERENCES:
patent: 4960787 (1990-10-01), Wasley
patent: 5534654 (1996-07-01), Ohtani et al.
patent: 6432999 (2002-08-01), Talley et al.
patent: 2002/0026052 (2002-02-01), Boschelli et al.
patent: 2005/0234033 (2005-10-01), Anandan et al.
patent: 2005/0288282 (2005-12-01), Delorme et al.
patent: 2006/0258728 (2006-11-01), Tani et al.
patent: 2007/0184979 (2007-08-01), Maier et al.
patent: 2008/0176848 (2008-07-01), Maier et al.
patent: 2009/0117074 (2009-05-01), Maier et al.
patent: 0 570 594 (1993-11-01), None
patent: 1 431 267 (2004-06-01), None
patent: 9312075 (1993-06-01), None
patent: 01/38322 (2001-05-01), None
patent: 0138323 (2001-05-01), None
patent: 03016254 (2003-02-01), None
patent: 03/024448 (2003-03-01), None
patent: 2004/037751 (2004-05-01), None
patent: 2004/046094 (2004-06-01), None
patent: 2005/020921 (2005-03-01), None
patent: 2005070900 (2005-08-01), None
patent: 2005/086898 (2005-09-01), None
patent: 2005087724 (2005-09-01), None
patent: 2006066189 (2006-06-01), None
patent: PCTEP2006060712 (2006-07-01), None
patent: PCTEP2006003171 (2006-08-01), None
patent: 2006097474 (2006-09-01), None
patent: 2006105979 (2006-10-01), None
patent: PCTEP2006066197 (2006-12-01), None
patent: 2007039404 (2007-04-01), None
Kubinyi (3D QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarity, vol. 2-3, Springer, 1998, 800 pages).
J. Almenara et al. “Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)”.Leukemia, vol. 16, pp. 1331-1343, 2002.
G. Bouchain et al. “Development of Potential Antitumor Agents. Synthesis and Biological Evaluation of a New Set of Sulfonamide Derivatives as Histone Deacetylase Inhibitors”.J. Med. Chem., vol. 46, pp. 820-830, 2003.
Y.L. Chung et al. “A Theraputic Strategy Uses Histone Deacetylase Inhibitors to Modulate the Expression of Genes Involved in the Pathogenesis of Rheumatoid Arthritis”.Molecular Therapy, vol. 8, pp. 707-717, 2003.
P. Dhordain et al. “The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression”.Nucleic Acids Research, vol. 26, No. 20, pp. 4645-4651, 1998.
W. Fischle et al. “Enzymatic Activity Associated with Class II HDACs is Dependent on a Multiprotein Complex Containing HDAC3 and SMRT/N-CoR”.Molecular Cell, vol. 9, pp. 45-58, 2002.
L. Gao et al. “Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family”.J. Biol. Chem., vol. 277, No. 28, pp. 25748-25755, 2002.
P. George et al. “Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3”.Blood, vol. 105, pp. 1768-1777, 2005.
K.B. Glaser et al. “Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA”.Biochemical and Biophysical Research Communications, vol. 310, pp. 529-536, 2003.
S. Haggarty et al. “Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation”.J. Proc. Natl. Acad. Sci. USA, vol. 100, No. 8, pp. 4389-4394, 2003.
L.Z. He et al. “Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL”.Nature Genetics, vol. 18, pp. 126-135, 1998.
E. Hockly et al. “Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease”.J. Proc. Natl. Acad. Sci. USA, vol. 100, No. 4, pp. 2041-2046, 2003.
R.W. Johnstone et al. “Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?”.Cancer Cell, vol. 4, pp. 13-18, 2003.
S. Khochbin et al. “Functional significance of histone deacetylase diversity”.Current Opinion Gen. Dev., vol. 11, pp. 162-166, 2001.
M.S. Kim et al. “Inhibition of Histone Deacetylase Increases Cytotoxicity to Anticancer Drugs Targeting DNA”.Cancer Research, vol. 63, pp. 7291-7300, 2003.
O.H. Kraemer et al. “Histone deacetylase as a therapeutic target”.Trends In Endocrin.&Metabol., vol. 12, No. 7, pp. 294-300, 2001.
G. Lagger et al. “Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression”.EMBO, vol. 21, pp. 2672-2681, 2002.
F. Leoni et al. “The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines”.Proc. Natl. Acad. Sci. USA, vol. 99, No. 5, pp. 2995-3000, 2002.
A. Mai et al. “3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 1. Design, Synthesis, Biological Evaluation, and Binding Mode Studies Performed through Three Different Docking Procedures”.J. Med. Chem.vol. 46, pp. 512-524, 2003.
A. Mai et al. “3-(4-Aroyl-1-methyl-1H-2-pyrroly)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 2. Effect of Pyrrole-C2and/or -C4Substitutions on Biological Activity”.J. Med. Chem., vol. 47, pp. 1098-1109, 2004.
P.A. Marks et al. “Histone Deacetylases and Cancer: Causes and Therapies”.Nature Reviews, vol. 1, pp. 194-202, 2001.
T.A. Miller et al. “Patent status of histone deacetylase inhibitors”.Expert Opin. Ther. Patents, vol. 14, No. 6, pp. 791-804, 2004.
T.A. Miller et al. “Histone Deacetylase Inhibitors”.J. of Med. Chem., vol. 46, No. 24, pp. 5098-5116, 2003.
N. Mishra et al. “Histone deacetylase inhibitors modulate renal disease in the MRL-1pr/1prmouse”.J. Clin. Invest., vol. 111, pp. 539-552, 2003.
C.S. Mitsiades et al. “Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications”.Proc. Natl. Acad. Sci. USA, vol. 101, No. 2, pp. 539-552, 2004.
P.N. Munster et al. “The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells”.Cancer Research, vol. 61, pp. 8492-8497, 2001.
T. Murata et al. “Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome”.Human Molecular Genetics, vol. 10, No. 10, pp. 1071-1076, 2001.
T. Nakayama et al. “Epigenetic Regulation of Androgen Recepter Gene Expression in Human Prostate Cancers”.Lab. Inv., vol. 80, No. 12, pp. 1789-1796, 2000.
R. Nimmanapalli et al. “Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells”.Cancer Research, vol. 63, pp. 5126-5135, 2003.
K. Nishida et al. “Histone Deacetylase Inhibitor Suppression of Autoantibody-Mediated Arthritis in Mice via Regulation of p16INK4aand p21WAF1/Cipl Expression”.Arthritis Rheumatism, vol. 50, No. 10, pp. 3365-3376, 2004.
R.L. Piekarz et al. “Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report”.Blood, vol. 98, pp. 2865-2868, 2001.
R. Ragno et al. “3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drug Design and Docking Studies”.J. Med. Chem., vol. 47, pp. 1351-1359, 2004.
C.M. Reilly et al. “Modulation of Renal Disease in MRL/1prMice by Suberoylanilide Hydroxamic Acid”.J. Immunol., vol. 173, pp. 4171-4178, 2004.
S. W. Remiszewski

Affiliated with

Also associated with

Rating

Sulfonylpyrroles does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sulfonylpyrroles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonylpyrroles will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4192399